Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes
| Autor: | F. E. Gianiorio, V. Patrone, C. G. Egan, Massimo Casu, G. Murialdo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Ambulatory blood pressure Endocrinology Diabetes and Metabolism Posture Blood Pressure Type 2 diabetes Orthostatic vital signs Basal (phylogenetics) Endocrinology Heart Rate Diabetes mellitus Internal medicine Internal Medicine medicine Heart rate variability Humans Aged Pioglitazone business.industry Heart General Medicine Middle Aged medicine.disease Blood pressure Diabetes Mellitus Type 2 Case-Control Studies Cardiology Female Thiazolidinediones business medicine.drug |
| Popis: | This study aims to examine the effect of pioglitazone on potential progression of autonomic damage in addition to changes in control of cardiovascular function in patients with type 2 diabetes (T2DM). Thirty patients with T2DM and 32 healthy subjects participated in the study. Sympathovagal activity, assessed by power spectral analysis (PSA) of R–R intervals variability, and blood pressure (BP) were studied during clinostatism and orthostatism in controls and patients. We have assessed blood pressure control by 24-hour monitoring of ambulatory blood pressure. Patients were treated with pioglitazone (30 mg/day) for 6 months, and then re-evaluated by PSA for heart rate variability (HRV). Reduced levels of HbA1c (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|